QUININE FORMULATIONS, METHOD OF MAKING, AND METHO OF USE THEREOF
Disclosed herein are quinine formulations and methods of using quinine formulations. Specifically disclosed herein are solid oral dosage forms which can be administered as a capsule or tablet, or alternatively as a sprinkle form with the patient experiencing little or no bitter taste. The dosage forms provide immediate release in vitro and in vivo.
1 . An oral quinine formulation, comprising:
a solid oral dosage form comprising a plurality of taste-masked coated subunits,
wherein each coated subunit comprises
a core subunit comprising quinine sulfate and a pharmaceutically acceptable excipient, and
a coating on the outside of the core subunit, wherein the coating is
a.) about 1 to about 7% weight gain based on the weight of the core subunit of a coating consisting essentially of a combination of ethylcellulose and hydroxypropyl methylcellulose, and optionally a plasticizer, stabilizer, an anti-tacking agent, a surfactant, or a combination thereof,
wherein the ethylcellulose and hydroxypropyl methylcellulose are in a weight ratio of about 2:1 to about 1:2; or
b.) about 6 to about 14% weight gain based on the weight of the core subunit of a coating consisting essentially of a combination of cellulose acetate phthalate and hydroxypropyl methylcellulose, and optionally a plasticizer,
wherein the cellulose acetate phthalate and hydroxypropyl methylcellulose are in a weight ratio of about 3:1 to about 1:1;
wherein the quinine formulation exhibits immediate-release profile, and
wherein the quinine formulation can be administered as a single unit solid oral dosage form or administered as a sprinkle on food.
2 . The quinine formulation of claim 1 , wherein the coating is
a.) about 2 to about 6% weight gain based on the weight of the core subunit of a coating consisting essentially of a combination of ethylcellulose and hydroxypropyl methylcellulose, and optionally a plasticizer, a stabilizer, an anti-tacking agent, a surfactant, or a combination thereof,
wherein the ethylcellulose and hydroxypropyl methylcellulose are in a weight ratio of about 1.5:1 to about 1:1.5; or
b.) about 8 to about 12% weight gain based on the weight of the core subunit of a coating consisting essentially of a combination of cellulose acetate phthalate and hydroxypropyl methylcellulose, and optionally a plasticizer,
wherein the cellulose acetate phthalate and hydroxypropyl methylcellulose are in a weight ratio of about 2.6:1 to about 2:1.
3 . An oral quinine formulation, comprising
a solid oral dosage form comprising a plurality of taste-masked coated subunits,
wherein each coated subunit comprises
a core subunit comprising quinine sulfate and a pharmaceutically acceptable excipient, and
a coating on the outside of the core subunit, wherein the coating is
about 3 to about 5% weight gain based on the weight of the core subunit of a coating consisting essentially of a combination of ethylcellulose and hydroxypropyl methylcellulose, and optionally a plasticizer, a stabilizer, an anti-tacking agent, a surfactant, or a combination thereof, and
wherein the ethylcellulose and hydroxypropyl methylcellulose are in a weight ratio of about 1.2:1 to about 1:1.2;
wherein the quinine formulation exhibits immediate-release profile, and
wherein the quinine formulation can be administered as a single unit solid oral dosage form or administered as a sprinkle on food.
4 . The quinine formulation of claim 1 , wherein the coating is
about 9 to about 11% weight gain based on the weight of the core subunit of a coating consisting essentially of a combination of cellulose acetate phthalate and hydroxypropyl methylcellulose, and optionally a plasticizer, and
wherein the cellulose acetate phthalate and hydroxypropyl methylcellulose are in a weight ratio of about 2.5:1 to about 2.1:1.
5 . The quinine formulation of claim 1 , wherein the coated subunits are minitablets having an average thickness of about 1750 micrometers to about 3000 micrometers.
6 . The quinine formulation of claim 1 , wherein the core subunit further comprises an intermediate coating comprising hydroxypropyl methylcellulose.
7 . The quinine formulation of claim 1 , wherein the coated subunits contain about 5 to about 12 mg quinine sulfate per unit.
8 . The quinine formulation of claim 1 , wherein the quinine sulfate has a particle size distribution where D(v,0.9) is less than 10 micrometers.
9 . The quinine formulation of claim 1 , wherein the formulation is a capsule comprising a plurality of coated subunits totaling about 324 mg quinine sulfate per capsule.
10 . The quinine formulation of claim 1 , wherein the formulation is bioequivalent to a reference drug according to New Drug Application No. 021799 (immediate release quinine sulfate capsule containing 324 milligrams quinine sulfate, 82 mg corn starch, 40 mg talc, and 4 mg magnesium stearate) when tested in a group of five or more healthy humans in the fasted or non-fasted state.
11 . The quinine formulation of claim 10 , wherein the 90% confidence limits of a ratio of a geometric mean of logarithmic transformed AUC 0-∞ of the formulation to a geometric mean of logarithmic transformed AUC 0-∞ of a reference drug according to New Drug Application No. 021799 is about 0.80 to about 1.25 when tested in a group of five or more healthy humans in the fasted or non-fasted state.
12 . The quinine formulation of claim 10 , wherein the 90% confidence limits of a ratio of a geometric mean of logarithmic transformed AUC 0-t of the formulation to a geometric mean of logarithmic transformed AUC 0-t of a reference drug according to New Drug Application No. 021799 is about 0.80 to about 1.25 when tested in a group of five or more healthy humans in the fasted or non-fasted state.
13 . The quinine formulation of claim 10 , wherein the 90% confidence limits of a ratio of a geometric mean of logarithmic transformed C max of the formulation to a geometric mean of logarithmic transformed C max of a reference drug according to New Drug Application No. 021799 is about 0.80 to about 1.25 when tested in a group of five or more healthy humans in the fasted or non-fasted state.
14 . The quinine formulation of claim 1 , wherein the 90% confidence limits of a ratio of a geometric mean of logarithmic transformed AUC 0-∞ of the quinine formulation when tested in a group of five or more healthy humans in the non-fasted state to a geometric mean of logarithmic transformed AUC 0-∞ of the quinine formulation when tested in a group of five or more healthy humans in the fasted state is about 0.80 to about 1.25.
15 . The quinine formulation of claim 1 , wherein the 90% confidence limits of a ratio of a geometric mean of logarithmic transformed AUC 0-t of the quinine formulation when tested in a group of five or more healthy humans in the non-fasted state to a geometric mean of logarithmic transformed AUC 0-t of the quinine formulation when tested in a group of five or more healthy humans in the fasted state is about 0.80 to about 1.25.
16 . The quinine formulation of claim 1 , wherein the 90% confidence limits of a ratio of a geometric mean of logarithmic transformed C max of the quinine formulation when tested in a group of five or more healthy humans in the non-fasted state to a geometric mean of logarithmic transformed C max of the quinine formulation when tested in a group of five or more healthy humans in the fasted state is about 0.80 to about 1.25.
17 . The quinine formulation of claim 1 , wherein the quinine formulation exhibits a dissolution profile such that after combining the formulation with 900 ml of 0.1N HCl, optionally containing pepsin (activity of pepsin between 607,500 to 750,000 Units per liter of dissolution medium), at 37° C.±0.5° C. using a tablet dissolution apparatus equipped with a basket stirring element, 100 rpm shaft speed, greater than or equal to 80% of the active agent is released within 60 minutes.
18 . The quinine formulation of claim 1 , wherein
wherein the quinine formulation leaches less than 0.6% quinine as determined by reverse-phase High Performance Liquid Chromatography (HPLC) analysis after 10 minutes from the time the formulation is mixed with four ounces of unsweetened applesauce as a sprinkle;
wherein the HPLC analysis is performed using a reverse-phase column at a column temperature of about 30° C.; a flow rate of 0.5 mL/minute; injection volume of 10 μL; detection at 249 nm; and mobile phase of 10 mM Ammonium Bicarbonate Buffer pH 9.5:Acetonitrile:Methanol (650:300:50); and
wherein the sample for the HPLC analysis comprises weighing a five gram aliquot of the applesauce ensuring no subunit is included in the aliquot; adding about 30 ml diluent (10 mM Ammonium Bicarbonate Buffer pH 9.5:Acetonitrile:Methanol (650:300:50)); shaking the flask for 15 minutes using a wrist action shaker; adding diluent to result in 50 ml volume; mixing; centrifuging a portion of the prepared sample at 3000 rpm for 15 minutes; and testing the supernatant by reverse-phase HPLC analysis.
19 . An oral quinine formulation, comprising:
a capsule comprising a plurality of taste-masked coated minitablets having an average thickness of about 1750 micrometers to about 3000 micrometers;
wherein each coated minitablet comprises
a core subunit comprising quinine sulfate and a pharmaceutically acceptable excipient, and a coating on the outside of the core subunit;
wherein the coating consists essentially of
a.) ethylcellulose and hydroxypropyl methylcellulose in a weight ratio of about 1.5:1 to about 1:1.5 and optionally a plasticizer, a stabilizer, an anti-tacking agent, a surfactant, or a combination thereof; or
b.) cellulose acetate phthalate and hydroxypropyl methylcellulose in a weight ratio of about 2.6:1 to about 2:1, and optionally a plasticizer;
wherein the quinine formulation exhibits immediate-release profile;
wherein the formulation comprises about 324 mg quinine sulfate per capsule; and
wherein the quinine formulation can be administered as a capsule or administered as a sprinkle on food.
20 . The quinine formulation of claim 19 , wherein
wherein the quinine formulation leaches less than 0.6% quinine as determined by reverse-phase High Performance Liquid Chromatography (HPLC) analysis after 10 minutes from the time the formulation is mixed with four ounces of unsweetened applesauce as a sprinkle;
wherein the HPLC analysis is performed using a reverse-phase column at a column temperature of about 30° C.; a flow rate of 0.5 mL/minute; injection volume of 10 mL; detection at 249 nm; and mobile phase of 10 mM Ammonium Bicarbonate Buffer pH 9.5:Acetonitrile:Methanol (650:300:50); and
wherein the sample for the HPLC analysis comprises weighing a five gram aliquot of the applesauce ensuring no minitablet is included in the aliquot; adding about 30 ml diluent (10 mM Ammonium Bicarbonate Buffer pH 9.5:Acetonitrile:Methanol (650:300:50)); shaking the flask for 15 minutes using a wrist action shaker; adding diluent to result in 50 ml volume; mixing; centrifuging a portion of the prepared sample at 3000 rpm for 15 minutes; and testing the supernatant by reverse-phase HPLC analysis.